News

American Association of Individual Investors1d
Why Inhibikase Therapeutics, Inc.’s (IKT) Stock Is Up 6.22%
Inhibikase Therapeutics, Inc.’s IKT share price has surged by 6.22%, which has investors questioning if this is right time to ...
Le Lézard4d
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)
Purcell & Lefkowitz LLP announces that it is investigating Inhibikase Therapeutics, Inc. on behalf of the company's shareholders. The investigation seeks to determine whether Inhibikase Therapeutics's ...
Inhibikase Therapeutics: A Hold With Uncertain Prospects In PAH
Inhibikase (IKT) pivots to IkT-001Pro for PAH amid competition like Merck’s sotatercept. Backed by $97.5M, results will ...
Investing24d
Inhibikase Therapeutics appoints new CFO
BOSTON - Inhibikase Therapeutics, Inc. (NASDAQ:IKT), a clinical-stage pharmaceutical company focused on developing treatments for pulmonary arterial hypertension (PAH), announced today the appointment ...
WIVB-TV25d
Inhibikase Therapeutics Announces Appointment of David McIntyre as Chief Financial Officer
BOSTON and ATLANTA, April 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company innovating small ...